» Articles » PMID: 11854183

Transcutaneous Immunization Using Colonization Factor and Heat-labile Enterotoxin Induces Correlates of Protective Immunity for Enterotoxigenic Escherichia Coli

Overview
Journal Infect Immun
Date 2002 Feb 21
PMID 11854183
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Enterotoxigenic Escherichia coli (ETEC) diarrheal disease is a worldwide problem that may be addressed by transcutaneous delivery of a vaccine. In several human settings, protective immunity has been associated with immune responses to E. coli colonization factors and to the heat-labile toxin that induces the diarrhea. In this set of animal studies, transcutaneous immunization (TCI) using recombinant colonization factor CS6 and cholera toxin (CT) or heat-labile enterotoxin (LT) as the adjuvant induced immunoglobulin G (IgG) and IgA anti-CS6 responses in sera and stools and antibody responses that recognized CS6 antigen in its native configuration. The antitoxin immunity induced by TCI was also shown to protect against enteric toxin challenge. Although immunization with LT via the skin induced mucosal secretory IgA responses to LT, protection could also be achieved by intravenous injection of the immune sera. Finally, a malaria vaccine antigen, merzoite surface protein 1(42) administered with CT as the adjuvant, induced both merzoite surface protein antibodies and T-cell responses while conferring protective antitoxin immunity, suggesting that both antiparasitic activity and antidiarrheal activity can be obtained with a single vaccine formulation. Overall, our results demonstrate that relevant colonization factor and antitoxin immunity can be induced by TCI and suggest that an ETEC traveler's diarrhea vaccine could be delivered by using a patch.

Citing Articles

A First in Human Clinical Trial Assessing the Safety and Immunogenicity of Two Intradermally Delivered Enterotoxigenic CFA/I Fimbrial Tip Adhesin Antigens with and without Heat-Labile Enterotoxin with Mutation LT(R192G).

Gutierrez R, Riddle M, Porter C, Maciel Jr M, Poole S, Laird R Microorganisms. 2023; 11(11).

PMID: 38004700 PMC: 10672875. DOI: 10.3390/microorganisms11112689.


Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization.

Prior J, Limbert V, Horowitz R, DSouza S, Bachnak L, Godwin M NPJ Vaccines. 2023; 8(1):80.

PMID: 37258506 PMC: 10231862. DOI: 10.1038/s41541-023-00677-z.


Immunological Evidence of Variation in Exposure and Immune Response to in Herbivores of Kruger and Etosha National Parks.

Ochai S, Crafford J, Hassim A, Byaruhanga C, Huang Y, Hartmann A Front Immunol. 2022; 13:814031.

PMID: 35237267 PMC: 8882864. DOI: 10.3389/fimmu.2022.814031.


Protective efficacy of a novel multivalent vaccine in the prevention of diarrhea induced by enterotoxigenic in a murine model.

Zhao H, Xu Y, Li G, Liu X, Li X, Wang L J Vet Sci. 2021; 23(1):e7.

PMID: 34841745 PMC: 8799940. DOI: 10.4142/jvs.21068.


CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine.

Gary E, Kathuria N, Makurumidze G, Curatola A, Ramamurthi A, Bernui M Vaccine. 2020; 38(11):2626-2635.

PMID: 32057572 PMC: 10681704. DOI: 10.1016/j.vaccine.2020.01.023.


References
1.
Glenn G, Taylor D, Li X, Frankel S, Montemarano A, Alving C . Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med. 2000; 6(12):1403-6. DOI: 10.1038/82225. View

2.
Hammond S, Tsonis C, Sellins K, Rushlow K, Scharton-Kersten T, Colditz I . Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev. 2000; 43(1):45-55. DOI: 10.1016/s0169-409x(00)00076-4. View

3.
Gockel C, Bao S, Beagley K . Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol Immunol. 2001; 37(9):537-44. DOI: 10.1016/s0161-5890(00)00074-2. View

4.
Hammond S, Walwender D, Alving C, Glenn G . Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine. 2001; 19(17-19):2701-7. DOI: 10.1016/s0264-410x(00)00506-5. View

5.
Beignon A, Briand J, Muller S, Partidos C . Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 2001; 102(3):344-51. PMC: 1783185. DOI: 10.1046/j.1365-2567.2001.01183.x. View